ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer.
ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer.
复制标题
DOI：
10.1038/bjc.2014.623
复制
发表时间：
2015-02-17
影响因子：
8.8
通讯作者：
Honda, K.
中科院分区：
文献类型：
--
作者：
Watanabe, T.;Ueno, H.;Watabe, Y.;Hiraoka, N.;Morizane, C.;Itami, J.;Okusaka, T.;Miura, N.;Kakizaki, T.;Kakuya, T.;Kamita, M.;Tsuchida, A.;Nagakawa, Y.;Wilber, H.;Yamada, T.;Honda, K.
关键词：
几项临床试验比较了局部晚期胰腺癌（LAPC）治疗的单独化疗和放化疗（CRT）。然而，LAPC最佳治疗的预测生物标志物仍有待确定。我们回顾性评估了ACTN4基因的扩增，以确定其作为LAPC预测生物标志物的有用性。应用荧光原位杂交技术检测91例LAPC患者治疗前的ACTN4拷贝数。单用化疗或联合CRT治疗的LAPC患者的总生存期（OS）或无进展生存期（PFS）无统计学显著差异。在接受CRT治疗的患者的亚组分析中，ACTN4拷贝数增加（CNI）的患者的OS预后比ACTN4拷贝数正常（NCN）的患者更差（P=0.0005，对数秩检验）。然而，在接受单独化疗的亚组中，CNI和ACTN4的NCN患者的OS无显著差异。在ACTN4的NCN患者中，CRT治疗患者的PFS中位生存时间长于单纯化疗患者（P=0.049）。ACTN4拷贝数是LAPC CRT的预测性生物标志物。
Several clinical trials have compared chemotherapy alone and chemoradiotherapy (CRT) for locally advanced pancreatic cancer (LAPC) treatment. However, predictive biomarkers for optimal therapy of LAPC remain to be identified. We retrospectively estimated amplification of the ACTN4 gene to determine its usefulness as a predictive biomarker for LAPC. The copy number of ACTN4 in 91 biopsy specimens of LAPC before treatment was evaluated using fluorescence in situ hybridisation (FISH). There were no statistically significant differences in overall survival (OS) or progression-free survival (PFS) of LAPC between patients treated with chemotherapy alone or with CRT. In a subgroup analysis of patients treated with CRT, patients with a copy number increase (CNI) of ACTN4 had a worse prognosis of OS than those with a normal copy number (NCN) of ACTN4 (P=0.0005, log-rank test). However, OS in the subgroup treated with chemotherapy alone was not significantly different between patients with a CNI and a NCN of ACTN4. In the patients with a NCN of ACTN4, the median survival time of PFS in CRT-treated patients was longer than that of patients treated with chemotherapy alone (P=0.049). The copy number of ACTN4 is a predictive biomarker for CRT of LAPC.
登录
查看更多内容
影响因子：
3.7
作者：
Honda K;Okusaka T;Felix K;Nakamori S;Sata N;Nagai H;Ioka T;Tsuchida A;Shimahara T;Shimahara M;Yasunami Y;Kuwabara H;Sakuma T;Otsuka Y;Ota N;Shitashige M;Kosuge T;Büchler MW;Yamada T
通讯作者：
Yamada T
影响因子：
3.8
作者：
Mayahara, Hiroshi;Ito, Yoshinori;Itami, Jun
通讯作者：
Itami, Jun
影响因子：
--
作者：
Otey, CA;Carpen, O
通讯作者：
Carpen, O
影响因子：
6.2
作者：
Colucci, G;Giuliani, F;Lopez, M
通讯作者：
Lopez, M
影响因子：
4.7
作者：
Mian, Omar Y.;Ram, Ashwin N.;Herman, Joseph M.
通讯作者：
Herman, Joseph M.